Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as J147 Emulsion for Injection
J147 Emulsion · 1 trial · 1 indication
Continuous vital signs, 12-Lead ECG, and laboratory assessments will be summarized using descriptive statistics, which includes count, mean, median, standard deviation, min and max by treatment arm and visits. Incidence and severity of adverse events and serious adverse events will be summarized with count and percentages by treatment arm, overall and by System Organ Class and Preferred Term. Deaths will be listed.
| Arm | Type | Description |
|---|---|---|
| Low Dose J147 | EXPERIMENTAL | J147 Emulsion for Injection, 1.6 mg/kg |
| Low Dose Placebo | PLACEBO_COMPARATOR | - |
| High Dose J147 | EXPERIMENTAL | J147 Emulsion for Injection, 2.5 mg/kg |
| High Dose Placebo | PLACEBO_COMPARATOR | - |
| Target Dose J147 | EXPERIMENTAL | J147 Emulsion for Injection |
| Target Dose Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| J147 Emulsion for Injection | DRUG | J147 Emulsion for Injection, 20 mg/mL for IV administration, low dose 1.6 mg/kg, high dose 2.5 mg/kg, single IV injection |
| Placebo | OTHER | Vehicle without J147, single IV injection |
Inclusion Criteria: * Signed informed consent obtained from the patient or legally authorized representative. * A new focal disabling neurologic deficit consistent with acute cerebral ischemia. * Baseline NIHSS ≥5 and ≤25 points obtained prior to randomization with a disabling neurological deficit ...
J147 Emulsion is an investigational small molecule being developed for the treatment of acute ischemic stroke. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is administered as an emulsion for injection.
J147 Emulsion is being developed by IQVIA Holdings, Inc., a company publicly traded under the ticker symbol IQV. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for acute ischemic stroke.
J147 Emulsion is currently in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. A Phase 2 clinical trial is planned to evaluate its safety and efficacy in patients with acute ischemic stroke.
J147 Emulsion is being studied in a Phase 2 clinical trial registered as NCT07430917, titled 'Safety and Efficacy of J147 in Acute Ischemic Stroke'. This randomized, double-blind, placebo-controlled trial plans to enroll 196 participants in the United States and is not yet recruiting.
Yes, J147 Emulsion is also known as J147 Emulsion for Injection. Both names refer to the same investigational drug being developed for acute ischemic stroke. The drug is currently in Phase 2 clinical development.